TAAR1 and schizophrenia: The authors find that sub-chronic ketamine treatment in mice produces elevated presynaptic dopamine function, characteristic of non-TRS patients, which is normalised following acute treatment with ulotaront/SEP-363856, a novel TAAR1 agonist schizophrenia therapeutic with a non-D2 mechanism of action [35, 130].